Impact of censoring data below an arbitrary quantification limit on structural model misspecification

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 35, Issue 1, 2008, Pages 101-116

  Byon, Wonkyung ^a,b   Fletcher, Courtney V ^c   Brundage, Richard C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

BQL; Censoring; LLOQ; Population pharmacokinetics; Structural model

Indexed keywords

ANALYTICAL ERROR; ARTICLE; COMPARTMENT MODEL; DATA ANALYSIS; DRUG RESEARCH; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; SIMULATION;

ANALYSIS OF VARIANCE; DATA INTERPRETATION, STATISTICAL; DRUG DESIGN; HUMANS; MODELS, STATISTICAL;

EID: 41049091516     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-007-9078-9     Document Type: Article

References (17)

1. FDA guidance for industry bioanalytical method validation. Available from http://www.fda.gov/cder/guidance/4252fnl.pdf Accessed on may 2001
2. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT and Yacobi A (2000). Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 17(12): 1551-1557
3. Hing JP, Woolfrey SG, Greenslade D and Wright PM (2001). Analysis of toxicokinetic data using NONMEM: impact of quantification limit and replacement strategies for censored data. J Pharmacokinet Pharmacodyn 28(5): 465-479
4. Beal SL (2001). Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5): 481-504
5. Duval V and Karlsson MO (2002). Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model. Pharm Res 19(12): 1835-1840
6. Beal SL (2005). Conditioning on certain random events associated with statistical variability in PK/PD. J Pharmacokinet Pharmacodyn 32(2): 213-243
7. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR and Brundage RC (2002). Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16(4): 551-560
8. Kakuda TN, Page LM, Anderson PL, Henry K, Schacker TW, Rhame FS, Acosta EP, Brundage RC and Fletcher CV (2001). Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother 45(1): 236-242
9. Zhou XJ, Sheiner LB, D'Aquila RT, Hughes MD, Hirsch MS, Fischl MA, Johnson VA, Myers M and Sommadossi JP (1999). Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 43(1): 121-128
10. Mirochnick M, Capparelli E and Connor J (1999). Pharmacokinetics of zidovudine in infants: a population analysis across studies. Clin Pharmacol Ther 66(1): 16-24
11. Capparelli EV, Englund JA, Connor JD, Spector SA, McKinney RE, Palumbo P and Baker CJ (2003). Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 43(2): 133-140
12. RETROVIR® prescribing information. Available from http://us.gsk.com/products/assets/us_retrovir.pdf Accessed on Nov 2006
13. Beal SL, Sheiner LB, Boeckmann AJ (eds) (1989-2006) NONMEM users guides. Icon development solutions. Ellicott City
14. Stram DO and Lee JW (1994). Variance components testing in the longitudinal mixed effects model. Biometrics 50(4): 1171-1177
15. Sheiner LB and Beal SL (1981). Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9(4): 503-512
16. ICH harmonized tripartitie guideline: validation of analytical procedures Q2(R1). Available from http://www.ich.org/LOB/media/MEDIA417.pdf
17. Fitzmaurice GM, Laird NM, Ware JH (2004) Applied longitudinal analysis. Wiley